Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers

BackgroundImmune checkpoint inhibitors (ICIs) have dramatically improved survival in advanced gastrointestinal (GI) cancer patients, but also resulted in immune-related adverse events (irAEs). This study aimed to evaluate serological biomarkers of irAEs and treatment response in GI cancer patients.P...

Full description

Bibliographic Details
Main Authors: Yanni Wang, Jianling Zou, Yun Li, Xi Jiao, Yujiao Wang, Na Zhuo, Mengting Gao, Jifang Gong, Jian Li, Xiaotian Zhang, Xicheng Wang, Zhi Peng, Changsong Qi, Zhenghang Wang, Jie Li, Yan Li, Lin Shen, Henghui Zhang, Zhihao Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
gastrointestinal cancers
immune checkpoint inhibitors
immune-related adverse events
biomarker
cytokines
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.987568/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.987568/full

Similar Items